Martin Currie Ltd. Increases Stock Position in IDEXX Laboratories, Inc. $IDXX

Martin Currie Ltd. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,254 shares of the company’s stock after acquiring an additional 3,039 shares during the quarter. IDEXX Laboratories accounts for approximately 1.7% of Martin Currie Ltd.’s holdings, making the stock its 20th largest position. Martin Currie Ltd.’s holdings in IDEXX Laboratories were worth $44,116,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Opal Wealth Advisors LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth $29,000. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories in the 2nd quarter worth about $36,000. NewSquare Capital LLC raised its position in IDEXX Laboratories by 87.5% in the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock worth $40,000 after buying an additional 35 shares during the last quarter. WPG Advisers LLC bought a new position in IDEXX Laboratories during the 1st quarter valued at about $37,000. Finally, Bank of Jackson Hole Trust grew its stake in shares of IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after acquiring an additional 69 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 1.1%

Shares of IDEXX Laboratories stock opened at $689.35 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $735.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a market capitalization of $55.05 billion, a P/E ratio of 57.40, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a fifty day moving average of $654.43 and a 200 day moving average of $594.06.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IDXX shares. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. UBS Group boosted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Piper Sandler reiterated a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Wednesday. Finally, Morgan Stanley lifted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.